Cargando…
Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures
OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprost...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381385/ https://www.ncbi.nlm.nih.gov/pubmed/30137264 http://dx.doi.org/10.1093/ejcts/ezy273 |
_version_ | 1783396482362114048 |
---|---|
author | Andreas, Martin Coti, Iuliana Rosenhek, Raphael Shabanian, Shiva Mahr, Stephane Uyanik-Uenal, Keziban Wiedemann, Dominik Binder, Thomas Kocher, Alfred Laufer, Guenther |
author_facet | Andreas, Martin Coti, Iuliana Rosenhek, Raphael Shabanian, Shiva Mahr, Stephane Uyanik-Uenal, Keziban Wiedemann, Dominik Binder, Thomas Kocher, Alfred Laufer, Guenther |
author_sort | Andreas, Martin |
collection | PubMed |
description | OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprosthesis. METHODS: Five hundred consecutive patients, of whom 45.6% were female with a mean age of 73.5 [standard deviation (SD) 7.9 years], with severe aortic stenosis who received a rapid deployment aortic valve between May 2010 and July 2017 were included in a prospective and ongoing database. The median follow-up time was 12 months, and the total accumulated follow-up time was 818 patient years. Preoperative characteristics, operative parameters, survival, valve-related adverse events and valve haemodynamics were assessed. RESULTS: Thirty-day mortality was 0.8% (4/500), and overall survival at 1, 3 and 5 years was 94%, 89% and 81%, respectively. A minimally invasive surgical approach was chosen in 236 patients (47%), of which 122 (24%) were operated on through an anterior right thoracotomy. Cross-clamp and cardiopulmonary bypass times for isolated aortic valve replacement were 53 (SD 17) and 89 (SD 29) min for full sternotomy as well as 75 (SD 23) and 110 (SD 31) min for minimally invasive surgery approaches (P < 0.001). Mean gradients at discharge, 1, 3 and 5 years were 13 (SD 5), 11 (SD 4), 12 (SD 5) and 11 (SD 3) mmHg, respectively. New pacemaker implantation was necessary in 8.6% of patients. A single case (0.2%) of structural degeneration was registered after 6 years. Valve explantation for non-structural dysfunction or endocarditis occurred in 9 patients (1.8%). CONCLUSIONS: This rapid deployment aortic valve has shown excellent results concerning haemodynamic performance, durability and safety. Implantation requires specific training, and the rate of pacemaker implantation remains a matter of concern. This novel valve also facilitates minimally invasive approaches and may be beneficial in complex combined procedures. |
format | Online Article Text |
id | pubmed-6381385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63813852019-02-25 Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures Andreas, Martin Coti, Iuliana Rosenhek, Raphael Shabanian, Shiva Mahr, Stephane Uyanik-Uenal, Keziban Wiedemann, Dominik Binder, Thomas Kocher, Alfred Laufer, Guenther Eur J Cardiothorac Surg Conventional Valve Operations OBJECTIVES: The Edwards INTUITY Valve System is a balloon-expandable bioprosthesis, inspired from the Edwards Magna valve and transcatheter technology, with a subvalvular stent frame to enable rapid deployment. We report a single-centre experience of aortic valve replacement with this novel bioprosthesis. METHODS: Five hundred consecutive patients, of whom 45.6% were female with a mean age of 73.5 [standard deviation (SD) 7.9 years], with severe aortic stenosis who received a rapid deployment aortic valve between May 2010 and July 2017 were included in a prospective and ongoing database. The median follow-up time was 12 months, and the total accumulated follow-up time was 818 patient years. Preoperative characteristics, operative parameters, survival, valve-related adverse events and valve haemodynamics were assessed. RESULTS: Thirty-day mortality was 0.8% (4/500), and overall survival at 1, 3 and 5 years was 94%, 89% and 81%, respectively. A minimally invasive surgical approach was chosen in 236 patients (47%), of which 122 (24%) were operated on through an anterior right thoracotomy. Cross-clamp and cardiopulmonary bypass times for isolated aortic valve replacement were 53 (SD 17) and 89 (SD 29) min for full sternotomy as well as 75 (SD 23) and 110 (SD 31) min for minimally invasive surgery approaches (P < 0.001). Mean gradients at discharge, 1, 3 and 5 years were 13 (SD 5), 11 (SD 4), 12 (SD 5) and 11 (SD 3) mmHg, respectively. New pacemaker implantation was necessary in 8.6% of patients. A single case (0.2%) of structural degeneration was registered after 6 years. Valve explantation for non-structural dysfunction or endocarditis occurred in 9 patients (1.8%). CONCLUSIONS: This rapid deployment aortic valve has shown excellent results concerning haemodynamic performance, durability and safety. Implantation requires specific training, and the rate of pacemaker implantation remains a matter of concern. This novel valve also facilitates minimally invasive approaches and may be beneficial in complex combined procedures. Oxford University Press 2019-03 2018-08-20 /pmc/articles/PMC6381385/ /pubmed/30137264 http://dx.doi.org/10.1093/ejcts/ezy273 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Conventional Valve Operations Andreas, Martin Coti, Iuliana Rosenhek, Raphael Shabanian, Shiva Mahr, Stephane Uyanik-Uenal, Keziban Wiedemann, Dominik Binder, Thomas Kocher, Alfred Laufer, Guenther Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
title | Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
title_full | Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
title_fullStr | Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
title_full_unstemmed | Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
title_short | Intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
title_sort | intermediate-term outcome of 500 consecutive rapid-deployment surgical aortic valve procedures |
topic | Conventional Valve Operations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381385/ https://www.ncbi.nlm.nih.gov/pubmed/30137264 http://dx.doi.org/10.1093/ejcts/ezy273 |
work_keys_str_mv | AT andreasmartin intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT cotiiuliana intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT rosenhekraphael intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT shabanianshiva intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT mahrstephane intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT uyanikuenalkeziban intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT wiedemanndominik intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT binderthomas intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT kocheralfred intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures AT lauferguenther intermediatetermoutcomeof500consecutiverapiddeploymentsurgicalaorticvalveprocedures |